Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) announced that CEO John Duke and Interim CFO Mark Frost will participate in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17, 2026.
A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET, with an audio-only webcast option available via the events and presentations section.
Details
News Market Reaction – HBIO
On Mar 3, the day this news came out, HBIO closed 4.31% below the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- Forum date
- March 17
- KeyBanc Capital Markets Virtual Healthcare Forum
- Fireside chat time
- 2:15pm ET
- Scheduled webcast from investor relations website
Historical Context
-
Set date for Q4 2025 results and earnings call webcast.
-
Preliminary Q4 beat on revenue and margins, EBITDA growth and 2026 focus.
-
Announced plant closure and global production shift for long-term savings.
-
Secured new $40.0M credit facility to refinance debt and extend maturities.
-
Reported net loss and goodwill impairment despite guidance and backlog strength.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17th. A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET that day.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Mark Frost
Interim Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.